Literature DB >> 11038197

Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model.

E Kebebew1, Q Y Duh, O H Clark.   

Abstract

There is a general consensus that total or near-total thyroidectomy is the optimal treatment for patients with high risk differentiated thyroid cancer (DTC), but the optimal extent of thyroidectomy in patients with low risk DTC continues to be controversial. To determine the optimal extent of thyroidectomy in patients with low risk DTC, we used decision analysis to compare the trade-offs of total thyroidectomy (TT) to thyroid lobectomy (TL). The decision analysis model included the probabilities of thyroidectomy complications, risk of DTC recurrence, and death from DTC. This information was obtained from the literature and from outcome data for patients with low risk DTC from our institution. In addition, the concept of utilities was used in the analysis. To determine the utility of each health outcome state (thyroidectomy complication, DTC recurrence, and DTC mortality for low risk patients) a survey was conducted. Overall, prospective patients viewed DTC recurrence as less desirable than thyroidectomy complication. The utilities assigned by the survey participants varied over a wide range, with 61.5% of the individuals viewing the occurrence of a thyroidectomy complication as better than DTC recurrence. At baseline utilities and probabilities, TT had a higher expected utility than TL. One-way sensitivity analysis varying the rates of (1) thyroidectomy complication, (2) DTC recurrence, and (3) DTC mortality over the possible range showed that complication from initial thyroidectomy was the most important factor that determined the preferred extent of thyroidectomy. TL was the preferred surgical approach only if a complication rate of > 33:1, TT/TL complication rate ratio, was assumed. When no differences in DTC recurrence between the two approaches was assumed in the model, TL had a higher expected utility using the baseline utilities of thyroidectomy complication and DTC mortality. The analysis indicates that TT in patients with low risk DTC is preferable to TL. However, TL is preferred if (1) no difference in the DTC recurrence rate between the two approaches is assumed, (2) a higher complication rate for TT is used (> 33 times higher), or (3) the utility ratio of thyroidectomy complication to DTC recurrence is < 0.8 TL. We believe this decision analysis model provides an objective approach that others can use to select the optimal extent of thyroidectomy based on patient preference of health outcome states, institution-specific outcome data for DTC recurrence or mortality, and the surgeon-specific complication rate.

Entities:  

Mesh:

Year:  2000        PMID: 11038197     DOI: 10.1007/s002680010215

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  12 in total

1.  Evaluation of intraoperative recurrent nerve monitoring in thyroid surgery.

Authors:  Guido Beldi; Thomas Kinsbergen; Rolf Schlumpf
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

Review 2.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

3.  A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.

Authors:  Katy Gallop; Cicely Kerr; Stacey Simmons; Bryan McIver; Ezra E W Cohen
Journal:  Qual Life Res       Date:  2014-08-09       Impact factor: 4.147

4.  Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.

Authors:  D P Momesso; F Vaisman; L S C Caminha; C H C N Pessoa; R Corbo; M Vaisman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

5.  Recombinant Parathyroid Hormone Versus Usual Care: Do the Outcomes Justify the Cost?

Authors:  Kathryn H Chomsky-Higgins; Holly M Rochefort; Carolyn D Seib; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Insoo Suh
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

6.  The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases.

Authors:  Eleni I Efremidou; Michael S Papageorgiou; Nikolaos Liratzopoulos; Konstantinos J Manolas
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

7.  Differentiated thyroid cancer: feasibility of loboisthmectomy in an endemic region.

Authors:  G Calò; E Erdas; F Medas; L Gordini; A Longheu; G Pisano; A Nicolosi
Journal:  G Chir       Date:  2015 Nov-Dec

8.  Is There Justification for Total Thyroidectomy in Low-Risk Papillary Thyroid Carcinoma? A Decision-Analysis Model.

Authors:  Sagit Stern; Ohad Hilly; Einav Horowitz; Moshe Leshno; Raphael Feinmesser
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

9.  Correlation Between Surgical Extent and Prognosis in Node-Negative, Early-Stage Papillary Thyroid Carcinoma Originating in the Isthmus.

Authors:  Seung Taek Lim; Ye Won Jeon; Young Jin Suh
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

10.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.